AU2005258005B2 - Anticancer and antiprotozoal dihydroartemisinene and dihydroartemisitene dimers with desirable chemical functionalities - Google Patents

Anticancer and antiprotozoal dihydroartemisinene and dihydroartemisitene dimers with desirable chemical functionalities Download PDF

Info

Publication number
AU2005258005B2
AU2005258005B2 AU2005258005A AU2005258005A AU2005258005B2 AU 2005258005 B2 AU2005258005 B2 AU 2005258005B2 AU 2005258005 A AU2005258005 A AU 2005258005A AU 2005258005 A AU2005258005 A AU 2005258005A AU 2005258005 B2 AU2005258005 B2 AU 2005258005B2
Authority
AU
Australia
Prior art keywords
compound
reaction
purification
followed
reaction mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2005258005A
Other languages
English (en)
Other versions
AU2005258005A1 (en
Inventor
Mahmoud A. Elsohly
Waseem Gul
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ElSohly Laboratories Inc
Original Assignee
ElSohly Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ElSohly Laboratories Inc filed Critical ElSohly Laboratories Inc
Publication of AU2005258005A1 publication Critical patent/AU2005258005A1/en
Application granted granted Critical
Publication of AU2005258005B2 publication Critical patent/AU2005258005B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2005258005A 2004-06-21 2005-06-21 Anticancer and antiprotozoal dihydroartemisinene and dihydroartemisitene dimers with desirable chemical functionalities Ceased AU2005258005B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58141204P 2004-06-21 2004-06-21
US60/581,412 2004-06-21
PCT/US2005/021826 WO2006002105A1 (en) 2004-06-21 2005-06-21 Anticancer and antiprotozoal dihydroartemisinene and dihydroartemisitene dimers with desirable chemical functionalities

Publications (2)

Publication Number Publication Date
AU2005258005A1 AU2005258005A1 (en) 2006-01-05
AU2005258005B2 true AU2005258005B2 (en) 2011-01-20

Family

ID=35782123

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005258005A Ceased AU2005258005B2 (en) 2004-06-21 2005-06-21 Anticancer and antiprotozoal dihydroartemisinene and dihydroartemisitene dimers with desirable chemical functionalities

Country Status (7)

Country Link
US (1) US7842720B2 (enExample)
EP (1) EP1753419B1 (enExample)
JP (1) JP5140416B2 (enExample)
AU (1) AU2005258005B2 (enExample)
CA (1) CA2570961C (enExample)
MX (1) MXPA06015060A (enExample)
WO (1) WO2006002105A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2899586B1 (fr) * 2006-04-11 2008-06-20 Sanofi Aventis Sa Dimeres de derives d'artemisinine, leur preparation et leur application en therapeutique
WO2009093629A1 (ja) * 2008-01-23 2009-07-30 Osaka University マラリアの予防または治療剤
US9422306B2 (en) 2012-12-21 2016-08-23 University Of Washington Through Its Center For Commercialization Artemisinin compounds and synthesis and use thereof
JP7548906B2 (ja) * 2018-12-21 2024-09-10 テラン バイオサイエンシズ インコーポレイテッド ボリナンセリンの重水素化形態および誘導体
JP7735183B2 (ja) * 2018-12-24 2025-09-08 ユーピーエル リミテッド アントラニルアミドの調製プロセス
JP7534726B2 (ja) * 2019-02-26 2024-08-15 マフムード エイ エルソーリー リーシュマニア症の処置用に選択されたアーテミシニンダイマー
KR102338609B1 (ko) * 2019-05-20 2021-12-14 보령제약 주식회사 피리도-피리미딘 화합물 및 이를 유효성분으로 포함하는 pi3k 관련 질환의 예방 또는 치료용 약학적 조성물

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040072896A1 (en) * 2002-10-15 2004-04-15 Elsohly Mahmoud A. Dihydroartemisinin and dihydroartemisitene dimers as anti-cancer and anti-infective agents

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5677468A (en) * 1995-06-29 1997-10-14 Hauser, Inc. Artemisinin dimer compounds having anticancer activity
US5840925A (en) * 1995-06-29 1998-11-24 Hauser, Inc. Trioxane dimer compounds having antiproliferative and antitumor activities
CN1084333C (zh) 1998-06-17 2002-05-08 中国科学院上海药物研究所 新的青蒿素化合物,其制备方法以及含有它们的药物组合物
US6878751B1 (en) * 2000-10-19 2005-04-12 Imperial College Of Science Technology And Medicine Administration of resveratrol to treat inflammatory respiratory disorders
FR2831538B1 (fr) 2001-10-26 2004-01-16 Centre Nat Rech Scient Nouveaux derives de l'artemisinine, et leurs utilisations dans le traitement du paludisme
US7417156B2 (en) 2002-09-27 2008-08-26 Johns Hopkins University Orally active, antimalarial, anticancer, artemisinin-derived trioxane dimers

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040072896A1 (en) * 2002-10-15 2004-04-15 Elsohly Mahmoud A. Dihydroartemisinin and dihydroartemisitene dimers as anti-cancer and anti-infective agents

Also Published As

Publication number Publication date
CA2570961C (en) 2015-09-01
EP1753419A4 (en) 2010-03-24
EP1753419A1 (en) 2007-02-21
US7842720B2 (en) 2010-11-30
AU2005258005A1 (en) 2006-01-05
CA2570961A1 (en) 2006-01-05
JP2008503582A (ja) 2008-02-07
WO2006002105A1 (en) 2006-01-05
MXPA06015060A (es) 2007-03-26
WO2006002105A8 (en) 2007-03-01
JP5140416B2 (ja) 2013-02-06
EP1753419B1 (en) 2014-01-15
US20080275106A1 (en) 2008-11-06

Similar Documents

Publication Publication Date Title
AU784589B2 (en) Bryostatin analogues, synthetic methods and uses
AU2003282543B2 (en) Dihydroartemisinin and dihydroartemisitene dimers as anti-cancer and anti-infective agents
EP2223929A1 (en) Gambogic glycoside derivatives and analogs, the preparation and the application thereof
JP2023030103A (ja) アムホテリシンｂの誘導体
EP3077402B1 (en) Anticancer maytansinoids with two fused macrocyclic rings
CN101481401A (zh) 雷公藤二萜类内酯衍生物、其药物组合物及其在抗生殖系统肿瘤中的应用
ITMI960338A1 (it) Derivati della camptotecina e loro uso come agenti antitumorali
US6051590A (en) Immunosuppressant tricyclic compounds
EP1753419B1 (en) Anticancer and antiprotozoal dihydroartemisinin and dihydroartemisitene dimers with desirable chemical functionalities
CN101613386A (zh) 藤黄酸环合类似物及其制备方法和应用
Fukamiya et al. Antitumor agents, 93. Bruceanol C, a new cytotoxic quassinoid from Brucea antidysenterica
US10493056B2 (en) Method of use of diterpenoid derivatives as anticancer agents
CN110343121B (zh) 双-(10-去氧双氢青蒿素)-间苯三酚缀合物的制备方法和应用
WO2008052352A1 (en) Substituted quinone indoleamine 2,3-dioxygenase (ido) inhibitors and syntheses and uses therefor
WO2000059501A1 (en) Water-soluble trioxanes as potent and safe antimalarial agents
CN109369667B (zh) 2，3，6-三脱氧糖基去甲表鬼臼毒素化合物及其制备方法和用途
El-Feraly et al. A new method for the preparation of arteether and its C-9 epimer
WO2009052507A1 (en) Bryostatin analogues, synthetic methods and uses
ElSohly et al. New orally active artemisinin dimer antimalarials
JP2009274956A (ja) ニーム種子由来の悪性腫瘍治療薬
JP2005314236A (ja) 新規クアシノイド系化合物及びそれらの用途
CN101861309A (zh) Salarin和tulearin以及它们的组合物和应用
Dejmek et al. Conformationally locked nucleoside analogues based on the bridgehead substituted 7-oxonorbornane and their antiviral properties
JPH069418A (ja) パナキンケコール化合物、及び制癌剤
GB2337752A (en) Immunosuppresant tricyclic compounds

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND INVENTOR NAMES FROM MAHMOUD, A. ELSOHLY; WASEEM, GUL TO ELSOHLY, MAHMOUD A. ; GUL, WASEEM.

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ ELSOHLY, MAHMOUD A. AND GUL, WASEEM

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired